rivastigmine
E115306
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| rivastigmine canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T972844 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rivastigmine Context triple: [Alzheimer's disease, canBeTreatedWith, rivastigmine]
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
C.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
D.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: rivastigmine Target entity description: Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
A.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
B.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
C.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
D.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
antidementia drug
ⓘ
approved drug ⓘ carbamate derivative ⓘ cholinesterase inhibitor ⓘ small molecule ⓘ |
| affectsSystem | central nervous system ⓘ |
| belongsToDrugClass |
acetylcholinesterase inhibitors
ⓘ
anticholinesterases ⓘ |
| hasATCCode | N06DA03 ⓘ |
| hasBioavailability | approximately 40 percent at therapeutic doses ⓘ |
| hasBrandName |
Exelon
ⓘ
Exelon Patch ⓘ |
| hasCASNumber | 123441-03-2 ⓘ |
| hasCommonSideEffect |
diarrhea
ⓘ
dizziness ⓘ loss of appetite ⓘ nausea ⓘ tremor ⓘ vomiting ⓘ weight loss ⓘ |
| hasContraindication |
known hypersensitivity to rivastigmine
ⓘ
previous allergic dermatitis from rivastigmine patch ⓘ |
| hasDosageForm |
capsule
ⓘ
oral solution ⓘ transdermal patch ⓘ |
| hasEliminationHalfLife | about 1.5 hours ⓘ |
| hasIUPACName | (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate ⓘ |
| hasMechanismOfAction |
inhibition of butyrylcholinesterase
ⓘ
reversible inhibition of acetylcholinesterase ⓘ |
| hasMolecularFormula | C14H22N2O2 ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasPrimaryMetabolite | NAP 226-90 ⓘ |
| hasProteinBinding | about 40 percent ⓘ |
| hasRouteOfAdministration |
oral
ⓘ
transdermal ⓘ |
| hasSeriousAdverseEffect |
bradycardia
ⓘ
gastrointestinal bleeding ⓘ syncope ⓘ |
| hasTitrationRequirement | dose must be increased gradually based on tolerability ⓘ |
| indicatedFor |
mild to moderate Alzheimer’s disease dementia
ⓘ
mild to moderate dementia associated with Parkinson’s disease ⓘ |
| isAdministeredWithFood | to improve gastrointestinal tolerability ⓘ |
| isExcretedVia | urine ⓘ |
| isMetabolizedBy | cholinesterase-mediated hydrolysis ⓘ |
| requiresCautionIn |
patients with asthma or obstructive pulmonary disease
ⓘ
patients with peptic ulcer disease ⓘ patients with sick sinus syndrome or conduction defects ⓘ |
| targets |
acetylcholinesterase
ⓘ
butyrylcholinesterase ⓘ |
| wasDevelopedBy | Novartis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: rivastigmine Description of subject: Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.